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SUPPLEMENTARY NOTE
ABSTRACT
This proposal was initially based on the IDEA award concept that the abnormal gene promoter DNA methylation status of the AP2 gene might predict which DCIS lesions in women would be at risk for the evolution of recurrence and/or emergence of invasive cancer. As the work progressed the concept was expanded to include the DNA methylation status of additional genes for this purpose and also for the purpose of predicting survival outcomes in women with all stages of breast cancer. During the course of the project, we performed a small nested case control study of 71 women with DCIS from USCF of which 34 developed recurrent disease. Unfortunately, among the methylation status of the AP2, CYCLIN D, ECAD, GSTP, and SSOCS genes, either as individual genes, or in combinations, no significant odds ratios for disease occurrence emerged when the predictive value of nuclear grade was factored in. We also performed a large blinded study of over 140 women with DCIS and all stages of breast cancer in a cohort from New Mexico with extensive 5 year longitudinal follow-up. Unfortunately, for all of the above genes plus 5 others, multivariate analyses, to date, do not show significant OR's for recurrence/survival. 
SUBJECT TERMS
Introduction
The overall purpose of this Idea Award was, as stated in the originally funded proposal, to determine whether hypermethylation of the AP-2α promoter and of other promoters where the marker incidence looks promising, could serve as molecular markers to predict the potential for breast DCIS (ductal carcinoma in-situ) lesions from individual patients to recur as invasive breast cancer. In-situ carcinomas account for approximately 20% of all newly diagnosed breast cancers in women. So the question of predicting which of these lesions which may progress, following initial surgery, to invasive breast cancers is an extremely important one especially since this may occur in some 15 to 20% of women diagnosed with DCIS. For our objective, we are employing a newly established, and highly sensitive, PCR assay for hypermethylation of AP-2α exon1, and for other candidate genes, which can be utilized on DNA scraped from slides prepared from paraffin blocks. In carrying out our overall objective, our study has three specific aims which have remained totally unchanged from the original proposal and these are:
Task/Specific Aim #1 -To verify the low incidence of AP-2α exon 1 hypermethylation in pure DCIS and compare this incidence in a progression model that assesses methylation in DCIS adjacent to and in the invasive cancer.
Task/Specific Aim #2 -To conduct a nested case control study, in collaboration with the UCSF Breast Cancer SPORE group, of AP-2α hypermethylation in DCIS samples from patients who have and have not manifested recurrent invasive disease.
Task/Specific Aim #3 -To conduct a prospective study of the predictive power for AP-2α hypermethylation in a cohort of women from the state of New Mexico with DCIS.
Body
During this award, we developed a panel of promoter DNA hypermethylated genes which, collectively, appeared to hold promise for predicting the behavior of DCIS. We utilized these markers during the grant to perform the following specific aims:
Specific Aims #1 and 2:
A. Work during the initial funding period: Over the cost of the regular funding period, we studied our gene panel for its predictive value in 70 extremely well annotated and followed patients from UCSF who had and had not gone on to recurrent disease and found performance of the individual genes is shown in Table 1 . Cyclin D and GSTPi together provided a 4.0 odds ratio (not shown) for recurrence but this was not as high as nuclear grade, the best clinical parameter, done on these same tumors from the patients. However, there was not a strict correlation between the two parameters and actually, when a multivariate analysis was done taking the hypermethylated genes and the nuclear grade parameter together (Table  2) , the hypermethylated genes still give an over 3.0 OR for disease recurrence. 
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These results are continuing to be analyzed by the UCSF group and it seems apparent that hypermethylated genes are picking up a group of patients that even nuclear grade does not. We believe another ~ 40 patients (half of who did and half who did not recur) will give us a final look at the results. We are encouraged that these will suggest that development of a panel of DNA hypermethylated genes can truly help evolve a better management of patients with DCIS.
Final no cost extension year:
The UCSF group considered all of the above analyses and concluded that the heavy contribution of nuclear grade made it unlikely that further sample analyses from their cohort, considering the precious nature of the small samples, would not be helpful. We thus turned to more DCIS samples from the New Mexico group, outlined in the next specific aim for further data concerning DCIS and the results are outlined in the aim below.
Specific Aim #3
A. Work during the initial funding period: To conduct a prospective study of the predictive power for AP-2α hypermethylation in a cohort of women from New Mexico with DCIS. This was the other ultimate study in the proposal utilizing the cohort from Dr. Belinsky in which DCIS samples, over 100, come from a 3,000 patient study of women with early stage breast cancer and/or DCIS in New Mexico. These patients have complete 5 year longitudinal follow-up and this has just been successfully complied into a finalized database. We now have actually studied all of the samples from all of the women with DCIS that have been identified. In addition to examining the methylation status of AP-2α , we have expanded the work to look at each of the other candidate genes in our panel discussed in detail in Specific Aims #1 and 2. The longitudinal data for recurrence are now in progress by Dr. Belinsky and his colleagues and we will match the results to our findings as soon as these are available. We now anticipate this match within the next four to six weeks.
Final no cost extension year:
We are still conducting assays and data analysis in the cohort but have broken the code on the numbers of samples we were able to process to date in the New Mexico cohort. First, we are addressing the question of women with DCIS to determine if we could further validate any trends seen in the UCSF study conducted in Specific Aim # 1. The data for AP2, alone are shown in Table 3 , and data from additional samples and the other genes are still pending at this time including evaluation for performance of groups of markers together. Unfortunately, the AP2 data do not show a positive correlation with recurrence, to date, as shown below. We have also done an analysis of AP2 results across all women analyzed in the cohort with all stages of breast cancer (Table 4) . Although there are positive trends for prediction We are also continuing analyses for the multiple markers performed in the New Mexico data for women with all stages of breast cancer and data for individual genes have just been done (Patient characteristics, Table 5 ; individual gene results, Table 6 ). Note: some missing data for age, BMI and the IHC variables. # Results missing for 7 to 23 specimens, depending on biomarker.
As can be seen, there are positive ratios for multiple genes (DapK, H-cad,cyclinD, and E-cad) which persist after the results have been adjusted for stage, although statistical significance foe each gene alone has not been reached. We have also been analyzing the data for stage 1 disease alone (Table 7) . Again, there are some important individual trends which could prove important but are not yet at statistical significance (note results for the GATA5, cyclinD, and especially the H-cad and E-cad genes).
We are now looking again at multivariate analyses for impact of other factors and, importantly, the results of gene combinations. We are also continuing to do sample analyses.
Key Research Accomplishments
As outlined above, during the no cost extension period we have been able to add quite a bit of data. 
Reportable Outcomes
The initial results upon which the Idea Award was based were published: 
Conclusions
The status of the work is outlined in the Key Research Accomplishments and can only be called promising for further development at this stage. We will continue the work as outlined and the analyses. Most important, this work and access to the New Mexico cohort has spurred our continued efforts to add new genes to our panel. By a random screening procedure of breast cancer cell lines for DNA hypermethylated genes, extrapolation of the data to primary samples, and matching of DNA methylation data to database microexpression arrays, we have important results. We have found that a series of genes which have recently been shown to have low frequencies of mutations in breast and/or colon cancers, in genome re-sequencing efforts (Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al.
